CN114601841A - Application of marsdenia tenacissima glycoside G in preparation of medicine for preventing and/or treating osteoarthritis - Google Patents
Application of marsdenia tenacissima glycoside G in preparation of medicine for preventing and/or treating osteoarthritis Download PDFInfo
- Publication number
- CN114601841A CN114601841A CN202210462700.7A CN202210462700A CN114601841A CN 114601841 A CN114601841 A CN 114601841A CN 202210462700 A CN202210462700 A CN 202210462700A CN 114601841 A CN114601841 A CN 114601841A
- Authority
- CN
- China
- Prior art keywords
- medicament
- glycoside
- marsdenia tenacissima
- osteoarthritis
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 49
- 241001125690 Marsdenia tenacissima Species 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 229930182470 glycoside Natural products 0.000 title claims abstract description 23
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- 230000001681 protective effect Effects 0.000 claims description 6
- 210000001188 articular cartilage Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 3
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229960001714 calcium phosphate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000000629 knee joint Anatomy 0.000 abstract description 26
- 210000001612 chondrocyte Anatomy 0.000 abstract description 24
- 210000005065 subchondral bone plate Anatomy 0.000 abstract description 12
- LJLXEAWGZFDUAP-ZYEUKROFSA-N 1-[(3s,8s,9s,10r,11s,12s,13s,14r,17r)-3,8,11,12,14-pentahydroxy-10,13-dimethyl-2,3,4,7,9,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C[C@H](O)CC2=CC[C@@]3(O)[C@@]4(O)CC[C@@H](C(=O)C)[C@@]4(C)[C@H](O)[C@@H](O)[C@@H]3[C@]21C LJLXEAWGZFDUAP-ZYEUKROFSA-N 0.000 abstract description 10
- LJLXEAWGZFDUAP-UHFFFAOYSA-N 17alpha-marsdenin Natural products C1CC(O)CC2=CCC3(O)C4(O)CCC(C(=O)C)C4(C)C(O)C(O)C3C21C LJLXEAWGZFDUAP-UHFFFAOYSA-N 0.000 abstract description 10
- RADWZEXHCQLYQI-UHFFFAOYSA-N Marsdenin Natural products CC(=O)C1CCC2(O)C3(O)CCC4=CC(O)CCC4(C)C3C(O)C(O)C12C RADWZEXHCQLYQI-UHFFFAOYSA-N 0.000 abstract description 10
- 210000002303 tibia Anatomy 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 238000010603 microCT Methods 0.000 abstract description 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 238000004043 dyeing Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 102000003777 Interleukin-1 beta Human genes 0.000 description 16
- 108090000193 Interleukin-1 beta Proteins 0.000 description 16
- 239000013641 positive control Substances 0.000 description 16
- 102000000503 Collagen Type II Human genes 0.000 description 11
- 108010041390 Collagen Type II Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100027995 Collagenase 3 Human genes 0.000 description 4
- 108050005238 Collagenase 3 Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 241001272720 Medialuna californiensis Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- -1 Trizol Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of marsdenia tenacissima glycoside G in preparation of a medicine for preventing and/or treating osteoarthritis, belonging to the technical field of preparation of medicines for preventing osteoarthritis. The invention compares the morphology of the tibia subchondral bone of the right knee joint of a mouse, the data of Micro-CT of the knee joint of the mouse, a dyeing result and OARSI scoring by setting a pseudo-operation control group and a DMM control group, detects the inflammatory factor expression in primary chondrocytes of the mouse and the condition of II type collagen in the primary chondrocytes, and evaluates the treatment effect of the marsdenin G on osteoarthritis.
Description
Technical Field
The invention belongs to the technical field of preparation of medicines for preventing osteoarthritis, and particularly relates to application of marsdenia tenacissima glycoside G in preparation of medicines for preventing and/or treating osteoarthritis.
Background
The Marsdenia tenacissima is dry rattan of Marsdenia tenacissima (Marsdenia tenacissima) of the family asclepiadaceae, is harvested in autumn and winter, has the effects of relieving cough and asthma, eliminating phlegm, promoting lactation, clearing away heat and toxic materials, is used for treating cough and asthma with excessive phlegm, postpartum galactostasis, rheumatic swelling and pain and sore carbuncle, and is a herbal plant widely distributed in many tropical and subtropical regions of Asia. Modern pharmacological research shows that the marsdenia tenacissima has obvious effects of resisting inflammation, detoxifying, relieving cough and asthma, resisting AIDS virus and resisting cancer. Marsdenia tenacissima glycoside G is a natural extract separated from Marsdenia tenacissima, is prepared by extracting stems of Marsdenia tenacissima with water, precipitating with ethanol and purifying, and has multiple active effects. Research data show that the marsdenia tenacissima G has the effects of resisting inflammation, cancer, tumor and the like, and currently, no report about the prevention of osteoarthritis by the marsdenia tenacissima G is found.
Osteoarthritis (OA) is a non-inflammatory degenerative joint disease in which a complex and dynamic set of biological and mechanical factors act together, and degeneration of cartilage is a central factor in the development of Osteoarthritis. The pathogenesis of OA is currently unclear, but many studies indicate that OA is closely related to the inflammatory pathway. The NF-kB transcription factor can activate chondrocytes in the joint degeneration and inflammation process by regulating downstream inflammatory mediators such as tumor necrosis factor-alpha, interleukin and Matrix Metalloproteinase (MMPs), promote the decomposition of joint cartilage and widely participate in OA pathophysiology so as to influence the process, thereby finding the important position of the NF-kB pathway in the OA molecular mechanism. Among them, the inflammatory cytokines IL-1 β and TNF- α play a key role in the pathological development of OA, and IL-1 β inhibits the synthetic activity of chondrocytes by down-regulating the synthesis of collagen type II and proteoglycan, which are major components of extracellular matrix (ECM), and also stimulates chondrocytes to release matrix metalloproteases such as MMP-13, thereby accelerating the degradation of chondrocyte extracellular matrix (ECM) by destroying collagen type II and proteoglycan in articular chondrocytes. In addition, IL-1 β stimulation of chondrocytes induces the release of COX-2 and nitric oxide synthase (iNOS), directly stimulating the overproduction of articular cartilage, synovial tissue, synovial fluid prostaglandin E2(PGE2) and Nitric Oxide (NO), which is also one of the major causes of pain in OA patients. A study also showed that IL-1 β and TNF- α were detected and significantly elevated in synovial membranes, subchondral bone and cartilage of OA patients. Thus, it is reasonable to believe that inhibition of IL-1 β and TNF- α -induced inflammatory mediators by the NF-. kappa.B pathway as a therapeutic target may attenuate OA progression.
The current clinical treatment of OA is mainly focused on pain relief, and treatment modalities include oral non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular injection of hyaluronic acid and steroids, with the treatment strategy at the end of the disease being joint replacement surgery. However, no effective drug is available for repairing and treating the cartilage destruction caused by OA. Therefore, there is an urgent need to identify an agent capable of preventing or treating OA to alleviate and reverse the progression of OA. Studies have shown that traditional chinese medicine treatment is safe and effective in improving pain, function and health in the OA treatment of the knee joint, and traditional chinese medicine shows lower risk of adverse events compared to standard western treatments. This is a unique advantage of traditional Chinese medicine. Therefore, how to deeply research the traditional Chinese medicine for preventing or treating OA becomes one of the important means for solving the problems.
Disclosure of Invention
In order to overcome the disadvantages of the prior art, the invention aims to provide the application of marsdenia tenacissima G in preparing the medicine for preventing and/or treating osteoarthritis.
In order to achieve the purpose, the invention adopts the following technical scheme to realize the purpose:
the invention discloses application of marsdenia tenacissima glycoside G in preparation of a medicine for preventing and/or treating osteoarthritis.
Preferably, the drug is a drug that inhibits the release of an inflammatory factor.
Preferably, the drug is a drug for protecting articular cartilage.
Preferably, the medicament is a medicament for alleviating joint pain.
Preferably, the medicament is a medicament for treating osteoarthritis, synovitis or degenerative joint disease.
Preferably, when the medicament is used for treating osteoarthritis, the dosage of the animal is 4-16 mug/kg.
The invention also discloses a medicament for preventing and/or treating osteoarthritis, which is prepared from marsdenia tenacissima glycoside G and pharmaceutically acceptable auxiliary materials.
Preferably, the auxiliary materials comprise more than one of starch, lactose, microcrystalline cellulose, dextrin, calcium phosphate, polyethylene glycol-4000, polyethylene glycol-6000, sodium carboxymethyl cellulose, hydroxypropyl cellulose or crospovidone.
Preferably, the medicament is in the form of tablets, capsules, granules, injections or pills.
Further preferably, in the injection, the marsdenia tenacissima glycoside G is prepared by dissolving marsdenia tenacissima glycoside G with the purity of more than 98% in 10% DMSO
Compared with the prior art, the invention has the following beneficial effects:
the application of the marsdenia tenacissima glycoside G in preparing the medicine for preventing and/or treating osteoarthritis is determined by evaluating the treatment effect of the medicine on osteoarthritis through investigating the expression of a primary chondrocyte inflammatory factor of a mouse, the expression of a primary chondrocyte type II collagen of the mouse, the cartilage morphology of the knee joint of an OA mouse, the Micro-CT result of the knee joint of the OA mouse, the HE staining, the SO staining and the OARSI scoring of knee joint slices of the OA mouse, and the marsdenia tenacissima glycoside G can be used for preparing the medicine for preventing osteoarthritis. The marsdenia tenacissima glycoside G can effectively relieve knee osteoarthritis symptoms of mice; reducing knee joint cartilage degeneration of the mice; the loss of type II collagen in knee joint cartilage of a mouse is reduced, the effects of remarkably improving cartilage damage and joint degeneration caused by osteoarthritis are achieved, and a new thought can be provided for the treatment of the osteoarthritis.
Drawings
FIG. 1 is a graph showing the results of the subchondral bone of the tibia of the right knee joint of a mouse in a Mirco-CT scanning sham operation group, a positive control group and a marsdenia tenacissima glycoside G group with different dosages;
FIG. 2 is a graph showing the change of solid content (BV/TV) in the tibial subchondral bone determined by the measurement of the results of the Mirco-CT scan of the tibial subchondral bone of the right knee joint of mice in the sham operation group, the positive control group and the different-dose marsdenine tenacissima G group according to the present invention; wherein A is the change in bone mass of the molded mouse at 4 weeks of administration, and B is the change in bone mass of the molded mouse at 8 weeks of administration;
FIG. 3 is a graph showing the HE staining and SO staining results of right knee joints of mice in a sham operation group, a positive control group and a different-dose marsdenia tenacissima glycoside G group according to the present invention;
FIG. 4 is a graph showing the results of OARSI scoring performed on SO-stained specimens of the right knee joints of mice in a sham operation group, a positive control group and a different-dose marsdenin G group in the present invention; wherein A is the OARSI score at 4 weeks of administration and B is the OARSI score at 8 weeks of administration;
FIG. 5 is a graph showing the inhibition of IL-1 β (20ng/mL) stimulated C57 mouse primary chondrocyte inflammatory factor by Marsdenia tenacissima G; wherein, A is the RNA expression of TNF-alpha, and B is the RNA expression of MMP-13;
FIG. 6 is a graph showing the protective effect of Marsdenia tenacissima G on type II collagen in primary chondrocytes of C57 mice stimulated with IL-1 β (20 ng/mL).
Detailed Description
In order to make the technical solutions of the present invention better understood, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that the terms "first," "second," and the like in the description and claims of the present invention and in the drawings described above are used for distinguishing between similar elements and not necessarily for describing a particular sequential or chronological order. It is to be understood that the data so used is interchangeable under appropriate circumstances such that the embodiments of the invention described herein are capable of operation in other sequences than those illustrated or described herein. Furthermore, the terms "comprises," "comprising," and "having," and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, method, system, article, or apparatus that comprises a list of steps or elements is not necessarily limited to those steps or elements expressly listed, but may include other steps or elements not expressly listed or inherent to such process, method, article, or apparatus.
The invention is described in further detail below with reference to the accompanying drawings:
example 1: marsdenia tenacissima glycoside G has protective effect on knee joint cartilage of C57 mouse subjected to OA model creation by comprehensive DMM operation
1. Experimental Material
C57 male mice (purchased from the Experimental animals center of Siann university of transportation), marsdenin G (purchased from Dougelip), chlortetracycline ointment, 10% DMSO, physiological saline, 10% chloral hydrate, 4% paraformaldehyde, microinjector, Mirco-CT (Sky-Scan 1276, Germany).
2. Experimental methods
In the experiment, a mouse knee joint OA model is established by adopting a DMM + ACTL-cut (comprehensive DMM) operation method.
The method comprises the following steps of randomly dividing 48C 57BL/6 mice into a Sham operation group (Sham + DMSO physiological saline injection at right knee joint), a positive control group (DMM + ACTL-cut + DMSO physiological saline injection at right knee joint), a marsdenin G low-dose group (DMM + ACTL-cut + marsdenin G injection at right knee joint) 4 mu G/Kg, a marsdenin G medium-dose group (DMM + ACTL-cut + marsdenin G injection at right knee joint) and a marsdenin G high-dose group (DMM + ACTL-cut + marsdenin G injection at right knee joint) 16 mu G/Kg).
Preparation of part of experimental reagents: DMSO physiological saline, dissolving 10% DMSO in 0.9% physiological saline at a ratio of 1: 1000; marsdenia tenacissima glycoside G injection: and dissolving the marsdenia tenacissima G crystal with the purity of more than 98 percent in 10 percent DMSO, and preparing according to different required drug concentrations.
C57BL/6 mice were treated with 4% chloral hydrate. After the mice are anesthetized to take effect, the mice are fixed on an operating table, a skin operation area is prepared, and the mice are fixed in a supine position. The method comprises the steps of taking the horizontal knee joint tibial plateau as a center, cutting skin along the inner side of the tibia, cutting off the inner collateral ligament, horizontally opening a knee joint cavity, dissociating an inner half-moon plate and separating from the middle position, separating the anterior cruciate ligament in the deep part of the joint cavity, closing the joint cavity, suturing the skin, and smearing aureomycin ointment on a cut after an operation to prevent infection. In the sham group, only the right skin and the joint capsule were incised and the joint was sutured after exposure. Injecting different doses of marsdenin G into the right knee joint of mice in the administration group for intervention on the second day after operation, injecting the same amount of DMSO physiological saline into the mice in the sham operation group and the positive control group, killing a certain number of mice in each group at the 4 th week and the 8 th week respectively, carrying out Mirco-CT analysis and various staining experiments, and carrying out OARSI scoring.
3. Results of the experiment
The results are shown in FIGS. 1 to 4. In fig. 1, the change of the morphology of the tibia subchondral bone of the right knee joint of all mice can be seen, the tibia subchondral bone of the combined DMM group is degenerated and the trabecular bone is lost compared with the tibia subchondral bone of the mice of the sham operation group, while the tibia subchondral bone degeneration of the mice of the dutasteride G group is reduced compared with the combined DMM group, and the trabecular bone is kept intact; as can be seen in fig. 2, the results of Mirco-CT scans measuring subchondral bone of the tibia in the right knee joint of mice: at week 4, the BV/TV ratio was elevated for all dosing groups relative to the combined DMM group, but there was no statistical difference. At week 8, the ratio of BV/TV (bone volume fraction) of the high dose group of Marsdenia tenacissima G (DMM + ACTL-cut + Marsdenia tenacissima G16 μ G/Kg) was higher than that of the comprehensive DMM control group, indicating that Marsdenia tenacissima G dose-dependent has protective effect on the bone content in subchondral bone of knee joint tibia in OA mice. The results of HE staining and SO staining of the subchondral bone of the tibia in the right knee joint of the mouse in fig. 3 show that the articular cartilage of the mouse is seriously damaged after the DMM operation, and the marsdenia tenacissima glycoside G has a protective effect on the articular cartilage. The results of OARSI scores in fig. 4 show that at week 4, the OARSI scores of the gougeron G medium-dose group and high-dose group were higher than those of the positive control group; at week 8, all mice with tenascin-G intervention had higher OARSI scores than the positive control.
Example 2: inhibition of IL-1 beta-stimulated C57 mouse primary chondrocyte inflammatory factor expression by Marsdenia tenacissima G
1. Experimental Material
IL-1 β (purchased from Proteitech, Inc.), 6-day old C57 suckling mice (purchased from Sigan university of transportation laboratory animals center), Marsdenia tenacissima G (purchased from Dougelip), 10% DMSO, DMEM-F12 medium, PBS solution, Trizol, chloroform, isopropanol, absolute ethanol, DEPC water, HiScript II Q RT Supermix for qPCR (+ gDNA wiper), SYBR II, real-time fluorescent quantitation PCR instrument (Bio-Rad, USA).
2. Experimental methods
(1) Preparing cells, resuspending mouse chondrocytes to 1X 106Inoculating cell suspension with cell/mL concentration into 6-well plate according to 2mL per well, dividing into blank control group, positive control group and administration group, and incubating for 12 hr;
(2) the marsdenia tenacissima G is prepared into 80mmol mother liquor by DMSO and then diluted by DMEM-F12 medium. The cells of the administered group were pretreated with Marsdenia tenacissima G (2.5. mu.M, 5. mu.M, 10. mu.M) for 2 hours, and the blank group and the positive control group were added with DMSO medium (1: 8000). Then using IL-1 beta with the concentration of 20ng/mL to induce chondrocytes of a positive control group and a dosing group for 48 hours;
(3) and (3) RNA extraction: resuspending and centrifuging the cells of the blank control group, the positive control group and the administration group, discarding the supernatant, washing twice by using PBS, adding 1ml of Trizol, standing for 5 minutes at room temperature, centrifuging at 12000rpm for 10min at 4 ℃, and sucking 1ml of the supernatant into an EP tube. Adding 200ul chloroform, vortexing for 15s, standing at room temperature for 3min, and centrifuging at 12000rpm for 10min at 4 ℃. And (3) sucking colorless supernatant (RNA) to a new sterile ribozyme-free centrifuge tube by adopting a small amount of method for many times. Adding isopropanol with the same volume as that of colorless supernatant RNA, slightly reversing and mixing, and standing on ice for 10min to fully precipitate the RNA. Centrifuging at 12000rpm at 4 deg.C for 10min, discarding the supernatant, washing with 0.8mL 75% ethanol (prepared in DEPC water) for 1 time, and washing with anhydrous ethanol once again. Placing in a super clean bench, naturally drying, adding 20 μ L DEPC water to dissolve RNA, and storing in a refrigerator at-80 deg.C.
(4) Taking 2 mu g of total RNA to prepare a reaction system according to the reverse transcription step, and carrying out reverse transcription reaction. The RNA expression and change of the Tongtong glycoside G to TNF-alpha in mouse cartilage cells induced by IL-1 beta are detected by a real-time fluorescent quantitative PCR instrument.
3. Results of the experiment
The results are shown in FIG. 5. FIG. 5 shows that 20ng/mL IL-1 β significantly increased RNA expression of inflammatory cytokines TNF- α and MMP-13 in C57 mouse primary chondrocytes relative to the blank control, while Marsdenia tenacissima G dose-dependently inhibited RNA expression of inflammatory cytokines TNF- α and MMP-13 in C57 mouse primary chondrocytes.
Example 3: protective effect of Marsdenia tenacissima glycoside G on type II collagen in primary chondrocytes of C57 mice stimulated by IL-1 beta
1. Experimental Material
IL-1 β (from Proteintech), 6-day old C57 suckling mice (from the center of the laboratory animals at the university of Sigan traffic), Marsdenia tenacissima G (from Dougelip), 10% DMSO, DMEM-F12 medium, PBS solution, 4% paraformaldehyde, Tween 20, Triton X-100, BSA (from Proteintech), Collagen Type II Polyclonal Antibody (28459-1-AP), Conjugated affinity Goat Antibody-Ranit IgG (SA00013-2), DAPI, fluorescent microscope.
2. Experimental method
(1) Preparing cells, resuspending mouse chondrocytes to 1X 104The cell suspension with cell/mL concentration was inoculated into a 6-well plate with a cover glass in an amount of 2mL per well, and the plate was divided into a blank control group, a positive control group and an administration group, and incubated for 12 hours；
(2) The marsdenia tenacissima G is prepared into 80mmol mother liquor by DMSO and then diluted by DMEM-F12 medium. The cells of the administered group were pretreated with Marsdenia tenacissima G (2.5. mu.M, 5. mu.M, 10. mu.M) for 2 hours, and the blank group and the positive control group were added with DMSO medium (1: 8000). Then using IL-1 beta with the concentration of 20ng/mL to induce chondrocytes of a positive control group and a dosing group for 48 hours; in PBS solution, the ratio of 1000: 1 add tween 20 to make PBST.
(3) Taking the cover glass pasted with the chondrocytes out of the six-hole plate, and washing for 5 minutes each time for 3 times by using PBS; cells were fixed with 4% paraformaldehyde for 15 min and permeabilized with 0.5% Triton X-100 in PBS for 60 min at room temperature; PBS was washed 3 times for 5 minutes each. PBST containing 5% BSA is dripped to block for 30 minutes; add primary Antibody (Collagen Type II Polyclonal Antibody, 1:200 dilution) and put in a wet box, incubate for 2 hours at room temperature; washing with PBS for 3 times, each time for 5 minutes, adding a fluorescent secondary antibody (Conjugated affinity Goat Anti-Rabbit IgG, diluted 1: 200), placing in a wet box, and incubating at 37 ℃ for 1 hour; adding DAPI dropwise, and incubating for 10 minutes at room temperature in a dark place; PBS washing removed excess DAPI, and the collected images were then viewed under a fluorescent microscope.
3. Results of the experiment
The results are shown in FIG. 6. Fig. 6 shows that the fluorescence expression of type II collagen in chondrocytes after 20ng/mL IL-1 β stimulation was reduced compared to the blank group, and the fluorescence expression of type II collagen in chondrocytes of the marsdenia tenacissima G-administered group was increased compared to the positive control group, and that the dose-dependent protection of type II collagen in primary chondrocytes of C57 mice by marsdenia tenacissima G was achieved.
The above-mentioned contents are only for illustrating the technical idea of the present invention, and the protection scope of the present invention is not limited thereby, and any modification made on the basis of the technical idea of the present invention falls within the protection scope of the claims of the present invention.
Claims (10)
1. Application of marsdenia tenacissima glycoside G in preparing medicine for preventing and/or treating osteoarthritis.
2. The use of claim 1, wherein the medicament is a medicament that inhibits the release of an inflammatory factor.
3. The use of claim 1, wherein the medicament is an articular cartilage protective medicament.
4. The use of claim 1, wherein the medicament is a joint pain-reducing medicament.
5. The use of claim 1, wherein the medicament is a medicament for the treatment of osteoarthritis, synovitis or degenerative joint disease.
6. The use according to claim 1, wherein the medicament is for animal administration in an amount of 4-16 μ g/kg for the treatment of osteoarthritis.
7. The medicine for preventing and/or treating osteoarthritis is characterized by being prepared from marsdenia tenacissima glycoside G and pharmaceutically acceptable auxiliary materials.
8. The use of claim 7, wherein the adjuvant comprises one or more of starch, lactose, microcrystalline cellulose, dextrin, calcium phosphate, polyethylene glycol-4000, polyethylene glycol-6000, sodium carboxymethylcellulose, hydroxypropylcellulose, or crospovidone.
9. The use of claim 7, wherein the medicament is in the form of tablets, capsules, granules, injections or pills.
10. The use of claim 9, wherein in the injection, the marsdenia tenacissima glycoside G is prepared by dissolving marsdenia tenacissima glycoside G with a purity > 98% in 10% DMSO.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210462700.7A CN114601841B (en) | 2022-04-28 | 2022-04-28 | Application of marsdenia tenacissima glycoside G in preparation of medicines for preventing and/or treating osteoarthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210462700.7A CN114601841B (en) | 2022-04-28 | 2022-04-28 | Application of marsdenia tenacissima glycoside G in preparation of medicines for preventing and/or treating osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114601841A true CN114601841A (en) | 2022-06-10 |
| CN114601841B CN114601841B (en) | 2024-06-21 |
Family
ID=81869893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210462700.7A Active CN114601841B (en) | 2022-04-28 | 2022-04-28 | Application of marsdenia tenacissima glycoside G in preparation of medicines for preventing and/or treating osteoarthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601841B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893191A (en) * | 2012-12-25 | 2014-07-02 | 广州中医药大学热带医学研究所 | Application of steroid compounds in preparation of antitumor chemotherapy drug synergists |
| CN105198954A (en) * | 2015-08-25 | 2015-12-30 | 中国人民解放军第二一〇医院 | C21 steroid compound in marsdenia tenacissima and preparation method and application thereof |
| CN109692181A (en) * | 2019-01-28 | 2019-04-30 | 河南中医药大学 | CAULIS MARSDENIAE TENACISSIMAE glycosides I or CAULIS MARSDENIAE TENACISSIMAE glycosides G is preparing the application in anti-inflammatory drug |
-
2022
- 2022-04-28 CN CN202210462700.7A patent/CN114601841B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893191A (en) * | 2012-12-25 | 2014-07-02 | 广州中医药大学热带医学研究所 | Application of steroid compounds in preparation of antitumor chemotherapy drug synergists |
| CN105198954A (en) * | 2015-08-25 | 2015-12-30 | 中国人民解放军第二一〇医院 | C21 steroid compound in marsdenia tenacissima and preparation method and application thereof |
| CN109692181A (en) * | 2019-01-28 | 2019-04-30 | 河南中医药大学 | CAULIS MARSDENIAE TENACISSIMAE glycosides I or CAULIS MARSDENIAE TENACISSIMAE glycosides G is preparing the application in anti-inflammatory drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114601841B (en) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008292407B2 (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
| US6165515A (en) | Method for treatment of osteoporosis | |
| WO2022242189A1 (en) | Application of exosomes derived from stem cells in preparing medicine for treating chronic obstructive pulmonary diseases | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| CN114601841B (en) | Application of marsdenia tenacissima glycoside G in preparation of medicines for preventing and/or treating osteoarthritis | |
| KR100394147B1 (en) | Pharmacolocial effect and extracting method for chronic osteoporosis and rhematoid arthritis treatment by constituent drugs of oriental medicine | |
| WO2021101802A2 (en) | Placental tissue particulate compositions and methods of use | |
| CN108939058A (en) | A kind of Chinese materia medica preparation and preparation method of promoting blood circulation and stopping pain | |
| CN106890189A (en) | Application of the chonglou saponin in antineoplastic sensitizer is prepared | |
| CN114869869B (en) | Application of Eugenol in prevention and/or treatment of osteoarthritis | |
| KR102507928B1 (en) | Composition for preventing or treating nasal polyp comprising extract of sargassum horneri | |
| CN117815261B (en) | New medical application of saw palmetto fruit extract and soft capsule thereof | |
| CN112870250B (en) | Composition for preventing and treating organ fibrosis and application and preparation thereof | |
| WO2022100399A1 (en) | Therapeutic application of cell-free fat extract to arthritis | |
| CN117838774B (en) | Formula medicine for preventing and treating neutrophil activity related diseases | |
| CN110755419B (en) | Application of Holly magnolia alcohol A or B in preparation of medicine for treating knee osteoarthritis | |
| CN107802632B (en) | Traditional Chinese medicine effective component composition for treating rheumatic arthritis and rheumatoid arthritis and application thereof | |
| Ezhned | Prospects for the use of phytopreparations in the treatment of type 2 diabetes | |
| CN116549552A (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| Labbad et al. | Extracorporeal Pulse Activation Therapy and Amniotic Extracellular Matrix Injection for post-traumatic subtalar joint osteoarthritis: A case study | |
| CN118217336A (en) | Application of morinda officinalis total iridoid glycoside in preparation of medicine for reducing toxic and side effects of methotrexate | |
| CN118903119A (en) | Application of transcription factor ZBTB20 inhibitor in preparation of medicines for preventing and/or treating osteoarthritis | |
| KR20220100547A (en) | Dried cell secretome for osteoarthritis treatment | |
| CN117838757A (en) | Medicine for treating rheumatoid arthritis | |
| CN118059189A (en) | Medicinal ink for preventing or treating pulmonary nodules and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |